BeiGene BGB-16673 CLL/SLL Phase 1 Clinical Trial Results 2024

Loading viewer...

conference

Format: PDF conference

Clinical trial results for BeiGene's BTK degrader BGB-16673 in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The study demonstrates the drug's efficacy in patients resistant to covalent and noncovalent BTK inhibitors through targeted protein degradation via polyubiquitination.

Browse all conferences →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from BeiGene

View all →

2023_CDISC-TMF%20Interchange_NNazim_FINAL

presentation

investor_presentation

Similar conferences from other companies

Browse all →

Absa Group 2008 UBS Financial Services Conference Presentation

conference

35 Pages

Absa Group

WIPO Madrid System Trademark Protection Webinar 2024

conference